Published in J Hepatol on July 01, 1990
Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables. Gut (1993) 0.91
Hepatitis C virus. A review. West J Med (1991) 0.75
Antibodies to hepatitis C virus and response to interferon treatment in non-A, non-B chronic hepatitis. J Hepatol (1991) 0.75
Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med (1993) 4.43
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med (1997) 3.49
Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a controlled study. N Engl J Med (1981) 3.13
Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther (2010) 2.94
Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol (2000) 2.68
Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology (1999) 2.63
Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology (1995) 2.54
Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis. Ann Surg (1991) 2.46
Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis (1986) 2.39
Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology (1991) 2.38
Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med (1985) 2.29
Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol (2006) 2.28
Propranolol--a medical treatment for portal hypertension? Lancet (1980) 2.27
Fatal exacerbation of chronic hepatitis B induced by recombinant alpha-interferon. Lancet (1991) 2.14
Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology (1980) 2.02
Ectopic varices in portal hypertension. Clin Gastroenterol (1985) 1.90
Acute hepatic necrosis and fulminant hepatic failure. Gut (1973) 1.87
The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology (2001) 1.87
Second generation (RIBA) test in diagnosis of chronic hepatitis C. Lancet (1991) 1.84
Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology (1988) 1.76
Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. Hepatology (1998) 1.74
A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med (1992) 1.71
Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology (1998) 1.69
A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C. Hepatology (2000) 1.67
Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut (2004) 1.65
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat (2005) 1.64
Cryoglobulinemia with vasculitis associated with hepatitis C virus infection. Gastroenterology (1993) 1.64
Immune complex type glomerulonephritis in cirrhosis of the liver. Am J Pathol (1975) 1.63
Liver adenomatosis. An entity distinct from liver adenoma? Gastroenterology (1985) 1.62
Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology (1986) 1.59
Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut (2009) 1.56
Emergency liver transplantation for fulminant hepatitis. Ann Intern Med (1987) 1.56
A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. Hepatology (1984) 1.56
Expression of complement-regulatory proteins in normal and UW-preserved human liver. Gastroenterology (1994) 1.54
Circulating soluble CR1 (CD35). Serum levels in diseases and evidence for its release by human leukocytes. J Immunol (1993) 1.53
Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology (1991) 1.52
Sclerosing cholangitis induced by formaldehyde solution injected into the biliary tree of rats. Arch Surg (1990) 1.52
Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol (2001) 1.51
Hepatitis C virus in patients with cryoglobulinemia type II. J Infect Dis (1990) 1.50
Randomized controlled trial of adenine arabinoside 5'-monophosphate in chronic active hepatitis B: comparison of the efficacy in heterosexual and homosexual patients. Hepatology (1989) 1.50
Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut (2004) 1.50
A controlled study of therapeutic portacaval shunt in alcoholic cirrhosis. Lancet (1976) 1.49
Peliosis hepatis in recipients of renal transplants. Gut (1978) 1.48
Propranolol in prevention of recurrent gastrointestinal bleeding in cirrhotic patients. Lancet (1981) 1.47
Influence of hepatitis G virus infection on the severity of liver disease and response to interferon-alpha in patients with chronic hepatitis C. Ann Intern Med (1997) 1.44
Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med (1996) 1.44
The effect of propranolol on portal hypertension in patients with cirrhosis: a hemodynamic study. Hepatology (1982) 1.44
Autoimmune chronic hepatitis exacerbated by alpha-interferon. Ann Intern Med (1992) 1.44
Transvenous liver biopsy: an experience based on 1000 hepatic tissue samplings with this procedure. Gastroenterology (1982) 1.43
[Adverse effects of proton pump inhibitors: should we worry about long-term exposure?]. Rev Med Interne (2012) 1.43
Relative risk of hepatocellular carcinoma in HBsAg positive vs alcoholic cirrhosis. A cross-sectional study. Liver (1990) 1.40
Exacerbation of multiple sclerosis after the administration of recombinant human interferon alfa. JAMA (1989) 1.38
Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology (1999) 1.35
Acute intravascular hemolysis and acute liver failure associated as a first manifestation of Wilson's disease. Ann Intern Med (1977) 1.31
Resection of presumed benign liver tumours. Br J Surg (1993) 1.29
Nodular regenerative hyperplasia of the liver. Report of six cases and review of the literature. Gastroenterology (1978) 1.29
Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut (1992) 1.28
Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology (1996) 1.26
Partial hepatectomy or orthotopic liver transplantation for the treatment of resectable hepatocellular carcinoma? A cost-effectiveness perspective. Hepatology (1998) 1.24
Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology (1992) 1.22
Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet (1991) 1.20
Heterozygous alpha 1-antitrypsin deficiency and cirrhosis in adults, a fortuitous association. Lancet (1975) 1.20
Choledocholithiasis: a prospective study of spontaneous common bile duct stone migration. Gastrointest Endosc (2000) 1.19
Hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria. A spectrum from asymptomatic occlusion of hepatic venules to fatal Budd-Chiari syndrome. Gastroenterology (1987) 1.18
Clinical course of spontaneous reactivation of hepatitis B virus infection in patients with chronic hepatitis B. Hepatology (1990) 1.16
Idiopathic portal hypertension (perisinusoidal fibrosis) after renal transplantation. Gut (1979) 1.15
Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. J Hepatol (2000) 1.15
[Hepatitis caused by diclofenac]. Gastroenterol Clin Biol (1983) 1.15
Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J Viral Hepat (2002) 1.14
Portosystemic shunt in Budd-Chiari syndrome: long-term survival and factors affecting shunt patency in 25 patients in Western countries. Surgery (1994) 1.13
Isolation, sequencing and analysis of the expression of Bryonia calmodulin after mechanical perturbation. Plant Mol Biol (1993) 1.13
Successful endoscopic obturation of gastric varices with butyl cyanoacrylate. Hepatology (1989) 1.13
Perhexiline maleate-induced cirrhosis. Gastroenterology (1979) 1.12
Portal hypertension in fulminant viral hepatitis. Gut (1980) 1.12
The intraportal lymphoid nodule and its environment in chronic active hepatitis C: an immunohistochemical study. Hepatology (1993) 1.12
Side-to-side portacaval shunt in the treatment of Budd-Chiari syndrome. Gastroenterology (1975) 1.12
Hepatic granulomas and hepatic sarcoidosis. Clin Liver Dis (2000) 1.12
Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut (2003) 1.11
Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol (1998) 1.11
Mechanism for reduced drug clearance in patients with cirrhosis. Gastroenterology (1978) 1.10
Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3. Histopathology (2001) 1.10
Comparison of the effects of a cardioselective and a nonselective beta-blocker on portal hypertension in patients with cirrhosis. Hepatology (1982) 1.09